1 Nicolucci A, Kovacs Burns K, et al. Research: Educational and Psychological Issues Diabetes Attitudes, Wishes and Needs second study. Diabet Med. 2013;30:767–777.
2 Close KL, Wood R. Outcomes Measures for New Diabetes Therapies Beyond A1c. Presented at: FDA; August 29, 2016; Silver Spring, MD.
https://diatribe.org/patient-priorities-diabetes-drugs-what-does-success-look. Accessed April 27, 2018.
3 Kaufman FR, Gibson LC, Halvorson M, et al. A pilot study of the continuous glucose monitoring system. Diabetes Care. 2001;24(12):2030-2034.
4 Cohen O. Guardian™ Connect CGM: Why prediction, education and data interpretation are key for sustained better outcomes. Presented at: 11th International
Conference on Advanced Technologies & Treatments for Diabetes; February, 2018; Vienna, Austria.
5 Cohen O, et al. ePoster presented at: 11th International Conference on Advanced Technologies & Treatments for Diabetes; February, 2018; Vienna, Austria.
IMPORTANT SAFETY INFORMATION
The Guardian Connect system requires a prescription and is indicated for continuous or periodic monitoring of glucose levels in the interstitial fluid under the skin, in patients (14 to 75 years of age) with diabetes mellitus. The system is intended to complement, not replace, information obtained from standard blood glucose monitoring devices, and is not recommended for people who are unwilling or unable to perform a minimum of two meter blood glucose tests per day, or for people who are unable or unwilling to maintain contact with their healthcare professional. The system requires a functioning mobile electronic device with correct settings. If the mobile device is not set up or used correctly, you may not receive sensor glucose information or alerts. For complete details of the system and its components, including warnings, contraindications, and precautions, please consult the user guide at http://www.medtronicdiabetes.com/support/download-library/user-guides and www.medtronicdiabetes.com/importantsafetyinformation.